Key insights
- Moderna President Stephen Hoge sold approximately $17 million in company stock between October 14-15, 2026, under a pre-arranged trading plan. The sales occurred as Moderna's stock has seen significant gains over the past year, though analysis suggests it may be overvalued. Hoge also exercised stock options during this period. The transactions could be perceived negatively by investors, despite being part of a planned strategy.
Stephen Hoge, President of Moderna, Inc. (NASDAQ:MRNA), recently sold company stock worth approximately $17.01 million, according to a Form 4 filing with the Securities and Exchange Commission. The transactions, which occurred on October 14 and October 15, 2026, also included the acquisition of shares through option exercises. The sales come as Moderna’s stock trades at $218.01, following a remarkable 738% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, with the company commanding a market capitalization of $94.42 billion.
On October 14, Mr. Hoge disposed of 38,774 shares of common stock at a weighted average price of $213.47, with individual sales ranging from $213.03 to $213.91. An additional 450 shares were sold on the same day at a weighted average price of $214.15, with prices ranging from $214.05 to $214.37. The following day, October 15, saw the sale of 39,145 shares at a weighted average price of $220.72, with prices ranging from $220.60 to $221.35. The total value of these sales amounted to approximately $17,013,537. InvestingPro Tips highlight that Moderna generally trades with high price volatility, which may explain the price variations during these transactions. The platform offers 14 additional exclusive tips for investors seeking deeper insights into the company’s prospects.
Concurrently, Mr. Hoge acquired 76,453 shares of common stock on October 14, 2026, and 76,452 shares on October 15, 2026, both through the exercise of stock options at a price of $12.21 per share. These option exercises represent a total value of approximately $1,866,970. The options were fully vested and exercisable.
All reported transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted on June 15, 2026.
Following these transactions, Mr. Hoge directly holds 1,636,565 shares of Moderna common stock. He also has indirect beneficial ownership of 4,116 shares through Valhalla, LLC, and 151,933 shares through a trust for the benefit of his spouse and children. Mr. Hoge disclaims Section 16 beneficial ownership of the shares held by the trust, except to the extent of his pecuniary interest. For comprehensive analysis, Moderna is one of over 1,400 US equities covered by InvestingPro’s detailed Research Reports, which transform complex data into actionable intelligence.
In other recent news, Moderna is set to join the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery. This change comes as Warner Bros. exits the index following Paramount-Skydance’s acquisition of the studio. In legal developments, a federal judge in Delaware declined to dismiss patent lawsuits against Pfizer, BioNTech, and Moderna concerning mRNA technology in their COVID-19 vaccines. The judge ruled that the companies did not sufficiently demonstrate the patent’s invalidity or lack of infringement at this stage. On the analyst front, Bernstein reiterated a Market Perform rating for Moderna, highlighting progress in its mRNA platform, particularly with Intismeran. UBS also maintained a Neutral rating on Moderna, with a focus on upcoming Phase III melanoma trial results. These developments provide investors with a detailed overview of Moderna’s current position and future prospects in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.